Multi4 is the first in the world to succeed in developing automated technology for endoscopic cancer diagnosis and treatment. The new and patented technology will be a game changer for millions of patients worldwide.
Bladder cancer ranks as the sixth most common cancer worldwide. 1 650 000 prevalent cases, 550 000 new cases and almost 200 000 deaths annually in 2018. 75% of all bladder cancer cases occur in men. It has a high recurrence rate with an average of 61% in year one and 78% over five years. Bladder cancer is the 6th most prevalent cancer in both sexes worldwide, the 4th in men.
Multi4 is a groundbreaking and multiple award-winning innovation for cancer diagnostics and treatment, especially suited for urinary bladder cancer. It’s a game-changer for patients, families, hospitals, medical professionals and society as a whole. Not only can it remove cancer tissue, it can also significantly reduce costs. Above all, Multi4 is designed to reduce human suffering and improve quality of life.
World-unique newly developed technology makes it possible to use the Multi4 instrument in the small working channel of a endoscope! The technology is generic and can later be used for cancer of the esophagus, stomach, lungs and intestines. With several robust patent families, the new technologies are well protected on the world market.
Multi4 is a powerful multipurpose instrument with 4 built-in functions. Apply local anesthesia, take tissue samples in a completely new way, automatically transport tissue samples through the instrument itself and destroy cancer tissue or stop bleedings with one single instrument. Multi4 is ergonomically designed with gender inclusion in mind. Regardless of your gender or handedness, the future is in the palm of your hand.
Multi4 doesn’t require the patient to wait for treatment, no fasting, no spinal or general anesthesia, no sterile surgery preparations, no operating room, and no catheter. When done with the treatment, the patient can go home, no need to stay in a hospital. Multi4 is developed to be used in outpatient care.
Performed in collaboration with RISE-research institute in Sweden, the University of Gothenburg Sweden and The Urology Clinic at Sahlgrenska University Hospital in Sweden.
Work is being done to meet both
MDR & FDA requirements.
Multi4 B is first launched in Sweden
and later in Europe.
Traditional bladder cancer diagnostics and treatment methods are expensive. Urinary bladder cancer has the highest per patient lifetime treatment costs of any cancer. The paper ”Economic Burden of Bladder Cancer Across the European Union” estimates that bladder cancer cost EU €4.9 billion in 2012. This amounted to 3 percent of all cancer costs.
It is estimated that upwards of $5.71 billion will be spent on bladder cancer in the US in the year 2020. The high cost shows the great need to improve the management of bladder cancer for the benefit of patients, healthcare systems and payers.
Today’s methods are both labor intensive and time consuming.
Multi4 cuts away many steps while adding value in the process.
Treatment is performed at the first visit in just 30 minutes in an outpatient setting.
There are many surgeries performed annually for bladder cancer, not least because the recurrence rate is so high. In the EU5 countries, 360,000 surgeries and in the United States, 315,000 are performed annually (transurethral resections of bladder cancer).
In addition, the world new Multi4-technology is scalable and can be used for cancer in other organs. The global market for endoscopes and associated equipment has an annual turnover of EUR 22,5 billion. Approximately 30% of this market. EUR 7 billion, consists of endoscopy accessories.
The market for diagnostic endoscopic biopsy instruments is expected to continue to grow from approximately EUR 1.5 billion in 2016 to approximately EUR 2.2 billion in 2022. Unfortunately, the number of cancer patients is increasing annually, new screening programs are introduced and the need for tissue sampling for diagnostics is increasing.
Multi4 collaborates with RISE – The research institute of Sweden.
RISE is a strong innovation partner who provides comprehensive support and a broad range of perspectives. RISE coordinates innovation research on Multi4 and assists with important regulatory expertise.
We work in parallel with many processes instead of serially to ensure a fast and high-quality journey towards launch so patients can get a treatment of their cancer without waiting times, in an easier way with less suffering , while healthcare and society save millions.
Don’t hesitate to contact us if you want to join our journey to fight cancer and reduce suffering for cancer patients around the world!
We are many who fight cancer together. We work with passion and we have a higher purpose.
In addition to a very driven management team that works operationally with a team of engineers, there are many people involved in the work every day. We work closely with two different patent office’s specializing in Med Tech to ensure a robust IP-portfolio. We have a fantastic main subcontractor who assists with high competence and work to produce a high-quality product.
Always available and so incredibly important are all colleagues in the healthcare sector, doctors, nurses, endoscopists and assistant nurses, but also directors, managers and professors who are engaged on demand from the start and help us move forward. You are all worth gold.